SCHEMBL2829436

SCHEMBL2829436

CC(C)Cc1ccc(CC(C)C)c(/C=C/C(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.59
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
TBXA2R P21731 4/20 0.42
PTGER3 P43115 4/20 0.42
PTGER2 P43116 4/20 0.42
PTGDR Q13258 4/20 0.42
PTGFR P43088 3/20 0.42
PTGER4 P35408 2/20 0.42
PTGS1 P23219 4/20 0.41
PTGS2 P35354 4/20 0.41
LMNA P02545 2/20 0.41
CYP2C9 P11712 2/20 0.41
AKR1C3 P42330 2/20 0.41
CXCR1 P25024 2/20 0.41
CXCR2 P25025 2/20 0.41
ALB P02768 1/20 0.41
ESR1 P03372 1/20 0.41
ALOX5 P09917 1/20 0.41
RARB P10826 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1716473 0.80 PTGER3 (0.56) TBXA2RPTGER3PTGER2PTGDRPTGFR
SCHEMBL17748553 0.78 KDM4E (0.50) PTGER3PTGER2PTGER4CA12CA1
SCHEMBL17748552 0.78 KDM4E (0.50) PTGER3PTGER2PTGER4CA12CA1
SCHEMBL764948 0.76 KDM4E (0.61) PTGS1PTGS2LMNACYP2C9AKR1C3
SCHEMBL7825300 0.76 KDM4E (0.61) PTGS1PTGS2LMNACYP2C9AKR1C3
SCHEMBL3637307 0.74 EGFR (1.00) EGFRTBXA2RPTGER3PTGER2PTGDR
SCHEMBL3637308 0.74 EGFR (1.00) EGFRTBXA2RPTGER3PTGER2PTGDR
SCHEMBL7138830 0.73 EGFR (0.59) EGFRTBXA2RPTGER3PTGER2PTGDR
SCHEMBL25146586 0.72 SMN1; SMN2 (0.56) PTGS1PTGS2LMNACYP2C9AKR1C3
SCHEMBL25146563 0.72 SMN1; SMN2 (0.56) PTGS1PTGS2LMNACYP2C9AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070079446-A1 Stabilized body care products, household products, textiles and fabrics CIBA SPECIALTY CHEMICALS CORP. 2007-04-12 US claimed
EP-1680541-A2 STABILIZED BODY CARE PRODUCTS, HOUSEHOLD PRODUCTS, TEXTILES AND FABRICS Ciba SC Holding AG (CH) 2006-07-19 EP claimed
WO-2005042828-A2 STABILIZED BODY CARE PRODUCTS, HOUSEHOLD PRODUCTS, TEXTILES AND FABRICS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-05-12 WO claimed
EP-0893119-B1 UV-protection formulation CIBA SC HOLDING AG (CH) 2003-09-03 EP claimed
US-11918672-B2 Water based concentrated product forms of oil-soluble organic UV absorbers BASF SE (DE) 2024-03-05 US disclosed
CN-111050742-B Water-based concentrated product forms of oil-soluble organic ultraviolet absorbers 巴斯夫欧洲公司 2023-06-30 CN disclosed
US-20200337974-A1 WATER BASED CONCENTRATED PRODUCT FORMS OF OIL-SOLUBLE ORGANIC UV ABSORBERS BASF SE (DE) 2020-10-29 US disclosed
CN-106999894-B Microcapsules 巴斯夫欧洲公司 2020-09-29 CN disclosed
EP-3227016-B1 MICROCAPSULES BASF SE (DE) 2020-08-26 EP disclosed
US-10709645-B2 Microcapsules BASF SE (DE) 2020-07-14 US disclosed
EP-3675808-A1 WATER BASED CONCENTRATED PRODUCT FORMS OF OIL-SOLUBLE ORGANIC UV ABSORBERS BASF SE (DE) 2020-07-08 EP disclosed
CN-111050742-A Water-based concentrated product form of oil-soluble organic UV absorber 巴斯夫欧洲公司 2020-04-21 CN disclosed
EP-1187598-A1 MICROPIGMENT MIXTURE Ciba SC Holding AG (CH) 2002-03-20 EP disclosed
WO-2001051013-A2 USE OF MICROBIALLY ENCAPSULATED MATERIALS IN COSMETIC END FORMULATIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-07-19 WO disclosed
US-6221342-B1 PROTECTING HUMAN AND ANIMAL SKIN AND HAIR FROM THE DAMAGING EFFECT OF UV RADIATION CIBA SPECIALTY CHEMICALS CORPORATION 2001-04-24 US disclosed
EP-1068866-A2 Use of mixtures of micropigments for prevening tannig and to induce skin and hair lightening Ciba SC Holding AG (CH) 2001-01-17 EP disclosed
WO-2000078277-A1 MICROPIGMENT MIXTURE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-12-28 WO disclosed
EP-1005325-A1 COSMETIC USE OF BIS(RESORCINYL)TRIAZINE DERIVATIVES Ciba SC Holding AG (CH) 2000-06-07 EP disclosed
EP-0956851-A1 Use of nanotopes in cosmetic products Ciba SC Holding AG (CH) 1999-11-17 EP disclosed
WO-1999008653-A1 COSMETIC USE OF BIS(RESORCINYL)TRIAZINE DERIVATIVES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070079446-A1 Stabilized body care products, household products, textiles and fabrics CUTA, NISCH, DSC1 EGFR 1870/4885GABRA1 4089/4885GABRB2 4345/4885
US-10709645-B2 Microcapsules ADH5, IPMK, CHKB EGFR 4276/4885GABRA1 2863/4885GABRB2 2443/4885
US-20200337974-A1 WATER BASED CONCENTRATED PRODUCT FORMS OF OIL-SOLUBLE ORGANIC UV ABSORBERS SSRP1, ACMSD, TST EGFR 3505/4885GABRA1 823/4885GABRB2 1059/4885
US-11918672-B2 Water based concentrated product forms of oil-soluble organic UV absorbers TST, SSRP1, SUPT16H EGFR 3542/4885GABRA1 902/4885GABRB2 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.